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Summary
Questions under study: In recent years, distress
and alexithymia have been recognised as psycho-
social factors related to both somatic and psycho-
somatic diseases. In this study distress and alex-
ithymia and their associations with physical pa-
rameters were investigated in lung recipients.
Methods: The study, which included 76 pa-
tients after a lung transplant,measured psycholog-
ical distress (Symptom Checklist, SCL-K-9) and
alexithymia (Toronto Alexithymia Scale, TAS-20).
Physical health was assessed by means of lung
function (FEV
1
), exhaled nitric oxide (eNO), and
comorbidity (CCI) at the time of the question-
naire survey. A bronchiolitis obliterans syndrome
(BOS) was assessed at the time of the question-
naire survey and one year later.
Results:Mean values of distress were found to
be significantly higher in lung recipients than in a
normal community sample, and mean values of
alexithymia were significantly higher in lung pa-
tients than in healthy persons. There is a signifi-
cant positive correlation between distress and
BOS at the time of the questionnaire survey (p =
.008). Distress is a predictor for new-onset BOS
one year after the questionnaire survey (p = .026).
No significant correlations were found between
alexithymia and physical parameters.
Conclusions: Lung transplants go hand in hand
with increased alexithymia and psychological dis-
tress. In addition, psychological distress may con-
tribute to the development of BOS. This associa-
tion underlines the importance of psychosocial
support after lung transplantation.
Key words: lung transplantation; alexithymia; dis-
tress; chronic rejection reaction; bronchiolitis obliterans
syndrome
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Introduction
Distress and alexithymia are well-known psy-
chological reactions to somatic diseases, as well as
being risk factors for the development of somatic
and psychosomatic diseases: distress, including
symptoms such as depression, anxiety, hostility, so-
matisation, interpersonal sensitivity and psychotic
ideation, is frequently found in patients with can-
cer, chronic pain, multiple sclerosis, and gastroin-
testinal diseases [1–4]. It is also a risk factor for
physical illnesses such as heart disease [5, 6]. After
an organ transplant, distress is seen as a typical re-
sponse to somatic strains and burdens caused by
surgery, immunosuppression and the side effects
of medication [7–11]. In some studies, pretrans-
plant distress predicts allograft rejection reactions
as well as higher posttransplant mortality [12–
15].
Alexithymia is described as an impaired capac-
ity for perceiving emotions [16]: alexithymic indi-
viduals are not able to recognise and verbalise
their emotions; they show very pragmatic thinking
and a lack of dreams. Today we differentiate be-
tween two types of alexithymia: firstly, alexithymia
is associated with a continuous deficit in the ante-
rior cingulate cortex [17]. From this point of view,
alexithymia is a stable personality characteristic
with an organic correlate. Secondly, alexithymia is
understood as a psychological “defence mecha-
nism” against severe emotional strains, caused for
example by physical diseases [18–20]. Although
alexithymia is seen in cancer, essential hyperten-
sion and psoriasis (e.g. 21–23), only very few stud-
ies have to date investigated alexithymia in trans-
plant patients. Kubo et al. [24] found that about
half of all patients receiving kidney transplants
suffered from alexithymia.According to Fukunishi
et al. [25], alexithymia was stronger before a liver
transplant than after. In a study of heart recipients,
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however, no differences were found before and af-
ter transplantation [26].
To our knowledge there have been no studies
on distress and alexithymia in lung recipients
which focus on interactions with physical health
after transplantation. Our first hypothesis in the
present study was that patients following a lung
transplantation experience increased distress and
alexithymia. Our second hypothesis was that these
psychosocial factors may contribute to the devel-
opment of a chronic rejection reaction, because
patients affected with psychosocial strains may be
more prone to nonadherence. Because cystic fi-
brosis (CF) patients differ physically from patients
with other lung diseases, and have coped with the
disease since their early years, we also looked for
differences between CF and other lung diseases in
terms of psychosocial variables.
The objective of the study was therefore to
answer the following questions:
1. How high are the levels of distress and alex-
ithymia in lung recipients? Are there differ-
ences in terms of distress and alexithymia be-
tween lung recipients suffering from CF and
recipients with other lung diseases?
2. What is the relationship between distress/
alexithymia and the patient’s physical health?
Are there correlations between distress/alex-
ithymia and the development of a chronic re-
jection reaction (BOS) one year after the
questionnaire survey?
Methods
Sample and procedure
Between November 1992 and December 2007, 200
patients underwent lung transplant surgery at Zurich
University Hospital.The inclusion criteria for the present
study were a time gap of three months or more between
operation and assessment, and an age of 16 years or more.
Sufficient knowledge of the German language was also re-
quired.After approval by the Ethics Committee of Zurich
University Hospital, patients were briefed by letter prior
to the study visit. The questionnaire was handed out dur-
ing a regular transplant consultation, at which time in-
formed consent was obtained (i.e. questionnaire survey,
T0). The physician in charge explained the study, and the
patients completed the anonymous questionnaire on the
same day. Current physical parameters were recorded on
the day of the questionnaire survey. In addition, the cor-
relation was calculated between distress/alexithymia and
the development of a new-onset BOS one year later (T1).
All patients without BOS at T0 were included in this cal-
culation (n = 65).
Measures
Psychosocial parameters
The Symptom Checklist (SCL-K-9) is a short ver-
sion of the Symptom Checklist SCL-90-R [27]. The
SCL-90-R measures psychological distress and psycho-
pathological symptoms in terms of hostility, obsessive-
compulsive symptoms, depression, interpersonal sensitiv-
ity, paranoid ideation, anxiety, somatisation, phobic anxi-
ety, and psychotic ideation. The German short version
SCL-K-9 is rated on a 5-point Likert scale between 0 (not
at all) and 4 (very much), and is computed by nine items
showing the highest correlation with the Global Severity
Index (GSI-90), a summary of the SCL-R-90 designed to
assess overall psychological distress over the preceding
seven days. A mean score for the 9 items is computed, the
potential range of scores is from 0 to 4; higher values in-
dicate higher distress. The SCL-K-9 has a one-dimen-
sional factor structure, a Cronbach’s Alpha of .87, and a
mean comparable to that of the GSI-90 [28].
The Toronto Alexithymia Scale (TAS-20) comprises
20 items rated on 5-point Likert scales ranging from 1
(strongly disagree) to 5 (strongly agree) [29, 30]. In addi-
tion to the total score (sum score for all 20 items, poten-
tial range of scores from 20 to 100), the TAS-20 yields
scores for three factor scales: difficulty identifying feelings
(DIF, sum score for 7 items, potential range from 7 to 35),
difficulty describing feelings (DDF, sum score for 5 items,
potential range 5–25), and externally-orientated thinking
(EOT, sum score for 8 items, potential range 8–40).
Scores on the TAS-20 are generally analysed as continu-
ous variables. Higher values indicate higher alexithymia,
more DIF, more DDF, and more EOT). There is a vali-
dated German version available with mean values of
healthy persons [31].
Physical parameters
The forced expiratory volume in one second (FEV
1
)
and exhaled nitric oxide (eNO) served as measures of pul-
monary function. Spirometry was performed with a mass
flowmeter (66200Autobox
®
, SensorMedics,Yorba Linda,
CA). Criteria for acceptability, reproducibility and pre-
dicted normal values were according to those of the Eu-
ropean Coal and Steel Community [32]; eNO, which we
assess on a routine basis during every consultation (Eco
Medics, CLD 88,Munich, Germany), is a nonspecific but
sensitive parameter of airway inflammation [33]. Further
diagnosis of the underlying disease leading to the lung
transplant and the date of surgery were recorded on the
day of the questionnaire survey. Bronchiolitis obliterans
syndrome (BOS) was looked for on the day of the ques-
tionnaire survey (T0) and one year later (T1). The term
“chronic rejection” (BOS) was used to describe the condi-
tion of BOS according to the criteria of the International
Society for Heart and Lung Transplantation [34]. Since
the number of lung recipients suffering from BOS is small
(8 patients with BOS grade I, 4 patients with BOS grade
II and 4 patients with BOS grade III), in our analysis we
only differentiated patients with BOS from those without
it. We also calculated the Charlson Comorbidity Index
(CCI) as used in studies including other adult solid organ
transplant recipients (i.e. liver, kidney) [35, 36]. Briefly,
comorbidities were defined as follows: chronic kidney dis-
ease (defined as serum creatinine of >130 mmol/l or a his-
tory of renal transplantation), insulin-dependent diabetes
mellitus, neoplasms (history of malignancy, excluding
non-melanoma skin cancer), peripheral vascular disease,
cerebral vascular disease, and coronary artery disease re-
spectively. The CCI was calculated by assigning a weight
of 2 to diabetes mellitus, renal insufficiency, malignancy
and stroke, and a weight of 1 to other comorbidities as de-
scribed previously elsewhere [36].
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Statistical analysis
The statistical evaluation was carried out with SPSS
12.0.1 forWindows.TheTAS-20 cut-off value was calcu-
lated according to the German validation study of Bach et
al. [32], following the calculation of Jacobson and Truax
[37]. Descriptive statistics data were expressed in absolute
numbers, percentage, means and 95% confidence inter-
vals, for comorbidity index median and interquartile
range (IQR). To compare patients with a sample of
healthy persons / psychiatric patients in the case of alex-
ithymia or a representative community sample in the case
of distress, the t-test for independent samples was used.To
compare CF patients with non-CF patients, an analysis of
covariance was performed (covariates: age, sex, time since
transplant). The correlations between variables were cal-
culated by Pearson’s correlation.
Results
Sociodemographic data, physical data, diagnoses
and comorbidity
Ninety-six of the 135 patients still living ful-
filled the inclusion criteria. Seventy-six of the 96
patients invited to participate in this survey did so,
yielding a response rate of 77%.The largest diag-
nostic group consisted of CF patients (n = 30,
40%), followed by those suffering from chronic
obstructive pulmonary disease (n = 26, 34%). Six-
teen patients (27.6%) were diagnosed with BOS
one year after this survey (T1), see table 1. In
terms of mean age, sex, lung function (FEV
1
) and
BOS we found no significant differences between
responders and nonresponders. Comorbidity: the
median of the CCI was 2 (IQR = 1–4), and the
most frequent comorbidities were chronic kidney
disease (creatinine >130) with 60.5% and insulin-
dependent diabetes mellitus with 34.2%.
Mean values and confidence intervals of
distress, alexithymia, and values of physical
parameters
Table 2 shows the mean values and confidence
intervals of distress, alexithymia, and physical pa-
rameters (FEV
1
, eNO), n = 76.
The mean value of psychological distress
(SCL-9-K) is significantly higher (p = 0.03) than
that of a German representative community sam-
ple (0.55 vs 0.39, p = 0.03). The values of this
community sample (n = 2057) are as follows: 56%
Table 1
Sociodemographic
data, physical data,
diagnoses and
comorbidity, n = 76.
Sociodemographic data Diagnoses
Sex Cystic fibrosis 30 (40%)
Female 33 (43%) COPD5 26 (34%)
Male 43 (57%) Pulmonary fibrosis 14 (18%)
Age in years (M, range) 45.3 (18–68) Pulmonary hypertension 3 (4%)
Other diagnoses 3 (4%)
Physical data Comorbidity
Time since Tx
1
in months (M, range) 50 (3-131) Charlson Index (CCI)
Median (interquartile range)
2 (1–4)
BOS (T0)
2
16 (21.1%) No comorbidity 18 (23.7%)
BOS (T1)
3
21 (27.6%) Chronic kidney disease (creatinin >130) 46 (60.5%)
Insulin-dependent diabetes mellitus 26 (34.2%)
Recent onset BOS (T0/T1) 4 5 (6.6%) Other comorbidities 11 (14.5%)
1
Tx = transplantation;
2
At the time of the questionnaire survey (T0);
3
One year after the questionnaire survey (T1);
4
Newly developed
BOS between T0 and T1;
5
COPD = chronic obstructive pulmonary disease.
Table 2
Mean values (M)
and 95% conﬁdence
intervals (CI) of
distress/alexithymia
and physical
parameters (lung
function FEV
1
, eNO)
atT0, n = 76.
Psychosocial
variables
M CI 95% for M Norm
4
M (Healthy persons)
5
M (Psychiatric patients)
5
SCL-K-9 .55 0.41;0.69 0.38
TAS-20 51.79 50.60;52.98 39.88 50.39
– DIF
1
15.67 15.00;16.35
– DDF
2
12.74 12.15;13.33
– EOT
3
23.38 22.83;23.93
Physical variables
FEV
1
2527 2354;2705
eNO 10.70 9.17;12.22
TAS-20:
1
Difficulty identifying feelings,
2
Difficulty describing feelings,
3
Externally orientated thinking,
4
Only available for SCL-K-9,
5
Only available for TAS-20 total score.
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females, average age 49 years; range 14–92, 58%
married, 8% jobless [28].The mean values of alex-
ithymia (TAS-20) among lung recipients (M 51.8)
are significantly higher than for German-speaking
healthy persons (p ≤.001; M 39.88; n = 221; 71%
females, average age 41 years, range 21–93; staff of
a hospital: n = 88; outpatients visiting the hospital
for a screening examination: n = 133; exclusion
criteria: psychiatric disorders) and German-speak-
ing inpatients of a university psychiatric hospital
(p = 0.028; M 50.39; n = 101; 67% females, aver-
age age 33 years, range 18–71; diagnoses: anxiety
disorder, n = 67; eating disorder, n = 17, somato-
form disorder, n = 7, alcohol abuse, n = 7, and dys-
thymia, n = 3). In our study 89.5% of all patients
had values >45 and were alexithymic according to
the German validation study of Bach et al. [31].
Compared to patients with other lung diseases in
our sample, CF patients show no significant dif-
ferences in terms of alexithymia and distress after
checking for age, sex and time since transplant
(analysis of covariance).
Correlations between distress/alexithymia and
physical parameters
Table 3 shows correlations between distress/
alexithymia and physical parameters (FEV
1
, eNO,
BOS and comorbidity) at the time of the question-
naire survey (T0).
Distress (SCL-K9) correlates positively with
the occurrence of a chronic rejection reaction
(BOS) at the time of the questionnaire survey
(T0). No significant correlation was found be-
tween distress/alexithymia on the one hand and
age/comorbidity on the other. Comorbidity is not
correlated with FEV
1
, eNO, BOS, age, and time
since transplantation.
The results of the bivariate analysis show that
psychological distress at the time of the question-
naire survey (T0) is significantly associated with
BOS one year after the survey (T1) (Pearson’s cor-
relation 0.324, p = 0.008). The correlations be-
tween alexithymia, age, time since transplant (T0)
and the diagnosis of CF on the one hand, and the
development of BOS one year later (T1) on the
other, are not significant.
Table 3
Correlations between
distress/alexithymia
and physical
parameters (lung
function FEV
1
, eNO,
BOS, Charlson Index
CCI) atT0, n = 76.
FEV
1
eNO BOS CCI
4
SCL-K-9 –.01 –.06 .23
x
–.03
TAS-20 .01 .08 .14 .03
– DIF
1
0 .01 .07 .09
– DDF
2
.08 .03 .11 –.06
– EOT
3
–.07 .14 .09 –.08
Legend: x p ≤.05; TAS-20:
1
Difficulty identifying feelings,
2
Difficulty describing feelings,
3
Externally orientated thinking,
4
Spearman’s rho.
Discussion
In this study we investigated the degree of dis-
tress and alexithymia among lung recipients and
the correlation with BOS both at the time of the
questionnaire survey and one year later. In sum-
mary we found high values of distress and alex-
ithymia after transplant, but no association be-
tween alexithymia and physical health. However,
chronic rejection reaction (BOS) goes hand in
hand with increased distress, and there seems to be
some indication that psychological distress may be
a contributing factor in the development of BOS.
Distress and alexithymia after lung
transplantation
Lung recipients report significantly higher
levels of psychological distress (SCL-K-9) than
normal controls. Strong psychological distress is
related to psychopathological symptoms (e.g. hos-
tility, compulsivity, depression, anxiety etc.). Psy-
chological distress may mirror problems in coping
with physical strains, e.g. fear of rejection reac-
tions or pulmonary infections. Comparison of CF
patients with lung recipients suffering from other
diseases shows that both groups experience similar
levels of alexithymia and stress.Although there are
physical and disease-related differences between
CF and non-CF patients before surgery, the emo-
tional reactions to a lung transplant in terms of
alexithymia and distress appear to be similar in
both groups. That lung recipients report higher
values for psychological distress compared to
norms is remarkable, because the majority of stud-
ies in lung transplantation have found that trans-
planted patients usually feel well and report a
good quality of life. In some studies it has been
found that these patients report the same or less
depression and anxiety compared with the general
population [8, 9, 38–40]. In contrast to other
measures (like the Hospital Anxiety and Depres-
sion Scale, for instance), the Symptom Checklist
SCL-K-9 seems to be a particularly appropriate
tool to assess psychopathological symptoms after
organ transplantation.
Why are most of the lung recipients alexi-
thymic? Most probably alexithymia is caused by
psychological defence mechanisms such as isola-
tion or denial of affects in stressful or harmful sit-
uations [18–20, 41]. Previous studies have revealed
that alexithymia may be induced by traumatic ex-
periences both during childhood and later in life
[42, 43]. Hence alexithymia in transplant patients
may be a psychological response mechanism for
coping with the stresses of the posttransplant life
situation. Compared to a study in kidney recipi-
ents [24], the frequency of alexithymia in our
study of lung recipients is clearly higher: in this
study some half of all patients receiving kidney
transplants suffered from alexithymia; in our study
386
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89% of the lung patients showed alexithymic
signs. Moreover, the mean values of TAS-20
among lung recipients in our study are higher
than the mean values of heart transplant patients
(51.8 vs 46.2) reported by Triffaux et al. [26].
These results show that transplant patients in gen-
eral suffer from alexithymia, but the values among
lung recipients seem to be particularly high. That
alexithymia is stronger before a liver transplant
than after [25] may indicate that liver recipients
now need fewer psychological defence strategies
(such as alexithymia), because their health situa-
tion is clearly improved.With respect to the cross-
sectional study design, we can only assume that af-
ter transplantation the majority of lung recipients
remain alexithymic, because some of their health
risks – such as pulmonary infections or BOS –
continue highly stressful. Future prospective stud-
ies should investigate the pre-/posttransplant de-
velopment of alexithymia in lung patients espe-
cially. Further,more psychologically subtle studies
are needed to answer the question whether pa-
tients after lung transplantation would feel them-
selves more threatened or more involved in medi-
cal procedures than other transplant patients, and
may therefore be more prone to react towards
these strains with alexithymia.
Associations between distress/alexithymia,
BOS and comorbidity
In this study significant positive correlations
were found between distress and current BOS, but
not between alexithymia and BOS. Theoretically
two types of interaction between distress and BOS
are possible: (1) patients affectedwith BOS aremore
likely to react with distress, and patients’ awareness
that they are suffering from BOS may provoke dis-
tress independently of current physical parameters
such as FEV
1
or eNO; (2) patients affected with dis-
tress may bemore prone to nonadherence,which in
turn may result in chronic rejection [cf. 44]. On the
other hand, we found no significant correlation be-
tween distress/alexithymia and the Charlson co-
morbidity index.Thus, for lung recipients the func-
tioning of their new organ seems to bemore impor-
tant than the strains of accompanying diseases or
drug side effects (= comorbidities).
The bivariate analysis regarding distress and
the development of BOS one year after the ques-
tionnaire survey underline this association be-
tween distress and BOS:The results show that dis-
tress is significantly correlated with BOS one year
later (T1), but not alexithymia or further sociode-
mographic or physical variables such as age, time
since transplant and diagnosis of cystic fibrosis.
One explanation could be that distressed patients
are not doing well medically at the time of the sur-
vey, e.g. are suffering from ischaemic injury or
pulmonary infections. These factors could be as-
sociated with increased distress at the time of the
survey as well as with the development of BOS
one year later. Nevertheless, there is no indication
that alexithymia is associated with the patient’s
current health status or may predict a future rejec-
tion reaction (BOS). Instead, it is probably the
overall physical or psychosocial strain experienced
by the patient after lung transplantation, rather
than the immediate lung function status, including
BOS, which reinforces alexithymia in lung recipi-
ents; in other words, alexithymia does not appear
to be a psychosomatic risk factor for the develop-
ment of BOS.
As for the limitations of the study, it must be
borne in mind that its explanatory power is re-
stricted by its cross-sectional nature at the time of
the questionnaire survey. Further, the correlation
between distress and BOS is rather weak. The re-
sults are limited by the relatively small sample of
lung recipients studied.Also, the small sample size
does not allow advanced analyses with multivari-
ate methods. In this context there is a lack of clear
causality regarding the connection between dis-
tress and the later development of BOS. The hy-
pothesis that distress may predict BOS should
therefore be tested in larger samples, assessing the
patients – as far as possible – at the same time
posttransplant.
Implications for psychosocial treatment and
further research
The results of our study show that alexithymia
and distress are typical reactions after lung trans-
plantation. Furthermore, psychological distress
may contribute to the development of a chronic
rejection reaction (BOS). Consequently, psycho-
social treatment should identify the main psycho-
logical sources of distress after lung transplanta-
tion, which may be related partly to transplant-
specific stress and partly to general psychological
problems aggravated by transplant experiences.
The importance of this psychosocial treatment is
highlighted by the finding that distress may con-
tribute to the development of a chronic rejection
reaction. Regarding alexithymia, it is well-known
that stressful experiences during illness and even-
tual transplantation are coped with by defence
mechanisms, and failure to process painful affects
may result in psychopathology. Here it is crucial
that patients learn through psychotherapy to per-
ceive, describe and integrate these emotional
equivalents.However, even if alexithymia were the
result of side effects, psychosocial treatment may
still help patients to process painful affects and in-
tegrate experiences related to the transplant or
other areas of their lives [45, 46].
Further research should address the question
whether psychological distress and alexithymia are
primary or secondary in nature (i.e. toxicity- or
emotion-based), or both. Studies could also in-
clude imaging methods. Prospective studies with
larger samples of lung patients should investigate
whether psychological distress actually contrib-
utes to the development of a chronic rejection re-
action (BOS), or if it instead represents a psycho-
logical reaction to the awareness that one is suffer-
ing from BOS.
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